Join Growin Stock Community!

Tonix pharmaceuticals holding corp.TNXP.US Overview

US StockHealthcare
(No presentation for TNXP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TNXP AI Insights

TNXP Overall Performance

TNXP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TNXP Recent Performance

0.93%

Tonix pharmaceuticals holding corp.

0.05%

Avg of Sector

-0.31%

S&P500

TNXP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TNXP Key Information

TNXP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TNXP Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Price of TNXP

TNXP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TNXP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.76
PE Ratio (TTM)
0.06
Forward PE
-
PS Ratio (TTM)
17.35
PB Ratio
0.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
34.31%
Net Margin
-963.38%
Revenue Growth (YoY)
-8.79%
Profit Growth (YoY)
50.90%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.76
PE Ratio (TTM)
0.06
Forward PE
-
PS Ratio (TTM)
17.35
PB Ratio
0.80
Price-to-FCF
-
Gross Margin
34.31%
Net Margin
-963.38%
Revenue Growth (YoY)
-8.79%
Profit Growth (YoY)
50.90%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TNXP's latest earnings report released?

    The most recent financial report for Tonix pharmaceuticals holding corp. (TNXP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TNXP's short-term business performance and financial health. For the latest updates on TNXP's earnings releases, visit this page regularly.

  • What is the operating profit of TNXP?

    According to the latest financial report, Tonix pharmaceuticals holding corp. (TNXP) reported an Operating Profit of -33.07M with an Operating Margin of -1,005.08% this period, representing a decline of 112.59% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TNXP's revenue growth?

    In the latest financial report, Tonix pharmaceuticals holding corp. (TNXP) announced revenue of 3.29M, with a Year-Over-Year growth rate of 16.58%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TNXP have?

    As of the end of the reporting period, Tonix pharmaceuticals holding corp. (TNXP) had total debt of 425K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TNXP have?

    At the end of the period, Tonix pharmaceuticals holding corp. (TNXP) held Total Cash and Cash Equivalents of 190.06M, accounting for 0.75 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does TNXP go with three margins increasing?

    In the latest report, Tonix pharmaceuticals holding corp. (TNXP) did not achieve the “three margins increasing” benchmark, with a gross margin of 58.4%%, operating margin of -1,005.08%%, and net margin of -972.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TNXP's profit trajectory and future growth potential.

  • Is TNXP's EPS continuing to grow?

    According to the past four quarterly reports, Tonix pharmaceuticals holding corp. (TNXP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -3.59. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TNXP?

    Tonix pharmaceuticals holding corp. (TNXP)'s Free Cash Flow (FCF) for the period is -29.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 58.13% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.